drugset / Trial / NCT04867980
A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants
RandomizedCrossoverQuadruple-blindTreatment
Summary
This study is to evaluate the effects of single therapeutic and supratherapeutic oral doses of ACP-196 on the heart rate-corrected QT interval using Fridericia's formula (QTcF).
Timeline
- Start
- 2016-04-01
- Primary completion
- 2016-05-09
- Completion
- 2016-05-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | 100 mg | Oral |
| Subject | Acalabrutinib | Small molecule | 400 mg | Oral |
| Subject | Moxifloxacin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.